Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Division of Pulmonary, Critical Care & Sleep Medicine, University of Washington School of Medicine, Seattle, Washington.
Cancer Res. 2022 Aug 16;82(16):2838-2847. doi: 10.1158/0008-5472.CAN-22-0554.
Genomic profiling of bronchoalveolar lavage (BAL) samples may be useful for tumor profiling and diagnosis in the clinic. Here, we compared tumor-derived mutations detected in BAL samples from subjects with non-small cell lung cancer (NSCLC) to those detected in matched plasma samples. Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) was used to genotype DNA purified from BAL, plasma, and tumor samples from patients with NSCLC. The characteristics of cell-free DNA (cfDNA) isolated from BAL fluid were first characterized to optimize the technical approach. Somatic mutations identified in tumor were then compared with those identified in BAL and plasma, and the potential of BAL cfDNA analysis to distinguish lung cancer patients from risk-matched controls was explored. In total, 200 biofluid and tumor samples from 38 cases and 21 controls undergoing BAL for lung cancer evaluation were profiled. More tumor variants were identified in BAL cfDNA than plasma cfDNA in all stages (P < 0.001) and in stage I to II disease only. Four of 21 controls harbored low levels of cancer-associated driver mutations in BAL cfDNA [mean variant allele frequency (VAF) = 0.5%], suggesting the presence of somatic mutations in nonmalignant airway cells. Finally, using a Random Forest model with leave-one-out cross-validation, an exploratory BAL genomic classifier identified lung cancer with 69% sensitivity and 100% specificity in this cohort and detected more cancers than BAL cytology. Detecting tumor-derived mutations by targeted sequencing of BAL cfDNA is technically feasible and appears to be more sensitive than plasma profiling. Further studies are required to define optimal diagnostic applications and clinical utility.
Hybrid-capture, targeted deep sequencing of lung cancer mutational burden in cell-free BAL fluid identifies more tumor-derived mutations with increased allele frequencies compared with plasma cell-free DNA. See related commentary by Rolfo et al., p. 2826.
支气管肺泡灌洗液 (BAL) 样本的基因组分析可能有助于临床肿瘤分析和诊断。在此,我们比较了非小细胞肺癌 (NSCLC) 患者 BAL 样本中检测到的肿瘤衍生突变与匹配血浆样本中检测到的突变。使用深度测序癌症个体化分析 (CAPP-Seq) 对 NSCLC 患者的 BAL、血浆和肿瘤样本中提取的 DNA 进行基因分型。首先对从 BAL 液中分离的游离 DNA (cfDNA) 的特性进行了表征,以优化技术方法。然后比较了肿瘤中鉴定的体细胞突变与 BAL 和血浆中鉴定的突变,并探讨了 BAL cfDNA 分析在区分肺癌患者和风险匹配对照方面的潜力。共对 38 例患者和 21 例接受 BAL 评估的对照者的 200 个生物样本和肿瘤样本进行了分析。在所有分期(P < 0.001)和 I 期至 II 期疾病中,BAL cfDNA 中鉴定出的肿瘤变异比血浆 cfDNA 中更多。21 例对照者中有 4 例 BAL cfDNA 中存在低水平的癌症相关驱动突变(平均变异等位基因频率[VAF] = 0.5%),提示非恶性气道细胞中存在体细胞突变。最后,使用具有留一法交叉验证的随机森林模型,在该队列中,BAL 基因组分类器以 69%的敏感性和 100%的特异性识别肺癌,并检测到比 BAL 细胞学更多的癌症。通过靶向测序 BAL cfDNA 检测肿瘤衍生突变在技术上是可行的,并且似乎比血浆分析更敏感。需要进一步的研究来确定最佳的诊断应用和临床实用性。
与血浆游离 cfDNA 相比,杂交捕获靶向深度测序肺癌突变负担可在 BAL 液体中检测到更多肿瘤衍生的突变,且等位基因频率更高。有关 Rolfo 等人的相关评论,见第 2826 页。